How safe is stem cell therapy for Degenerative Disc Disease?
Stem cell therapy for degenerative disc disease has shown a favorable safety profile in randomized clinical trials.

A 2026 meta-analysis of seven randomized trials with 594 patients found no meaningful differences in adverse events, serious complications, treatment discontinuation or mortality between patients who received intradiscal mesenchymal stromal cells (MSCs) and those in control groups. The most common side effect is a temporary increase in back or neck pain for several days to two weeks after the procedure. Because spinal injections involve delicate structures, the main risks come from the procedure itself: rare complications such as disc infection (discitis), bleeding, nerve irritation or headache. These risks are reduced by fluoroscopic (live X-ray) guidance, strict sterile technique, careful patient selection and performance by an experienced spine and pain specialist in an appropriate hospital setting, which is how Stem Cell Mexico performs spinal procedures.
This guide explains what the research shows, which risks are specific to spinal procedures, and how they are minimized.
What research shows about safety
Randomized evidence
A systematic review and meta-analysis published in the Asian Spine Journal in 2026 (Rahyussalim and colleagues) pooled seven randomized controlled trials of intradiscal MSC injections for chronic low back pain from degenerative disc disease. Beyond showing greater reductions in pain and disability than control treatments, the analysis found no meaningful differences in adverse events, serious complications, discontinuations or deaths between groups.
Broader clinical studies
Systematic reviews of clinical studies on MSCs for discogenic low back pain report a generally favorable safety profile across different cell sources (bone marrow, adipose and umbilical cord), doses and techniques, while noting that studies vary considerably and that long-term follow-up remains important.
What this means
In controlled settings, the cells themselves have not been associated with significant harm in disc disease. Most risk relates to the injection procedure and patient factors, which can be managed with proper technique and screening.
Common, temporary side effects
- Post-procedure pain flare: increased back or neck pain, sometimes with muscle spasm, often for three days to two weeks. It reflects the injection and local inflammatory response.
- Soreness at needle entry points.
- Temporary stiffness and difficulty sitting for long periods.
- Mild fatigue after sedation or after an added intravenous infusion.
These effects usually respond to rest, gentle movement, short periods of heat or ice after the first days (as instructed) and paracetamol.
Rare but important procedure risks
Disc infection (discitis)
Introducing a needle into the disc carries a small risk of infection. Discitis is rare with strict sterile technique but can cause severe, worsening back pain, fever and the need for antibiotics. This is one of the main reasons spinal injections should only be performed by experienced specialists in an appropriate setting.
Nerve irritation or injury
Nerve roots run close to the discs and facet joints. Temporary tingling or pain down the leg or arm can occur; permanent nerve injury is very rare with image guidance.
Bleeding
Small hematomas can form, especially in people taking blood thinners. Medications are reviewed and managed in advance.
Dural puncture headache
If the needle inadvertently passes into the membrane around the spinal fluid, a positional headache can occur. It usually resolves with rest, fluids and simple measures.
Sedation-related risks
Mild sedation is monitored by trained personnel; risks are low but are reviewed before treatment, especially in patients with sleep apnea, heart or lung disease.
Radiation exposure
Fluoroscopy uses low doses of X-ray for guidance. Exposure is kept as low as possible and is generally comparable to a few standard X-rays.
Cervical versus lumbar procedures
Safety considerations differ between regions of the spine. Lumbar (lower back) discs are larger and further from the spinal cord, which ends around the first or second lumbar vertebra, so lumbar procedures are more commonly performed in regenerative protocols. Cervical (neck) discs are smaller and close to the spinal cord, major arteries and nerves supplying the arms, so cervical injections require particular expertise, precise imaging and careful patient selection. In some cases, the doctor may recommend treating structures around the cervical disc, such as the facet joints, rather than injecting into the disc itself. Ask your doctor which approach is planned for each region and why.
How we reduce risk
- Specialist review of recent imaging: an MRI no older than three months is required to confirm which levels and structures are involved and to rule out conditions that need surgery, such as severe instability or significant nerve compression.
- Careful candidate selection: patients with active infection, uncontrolled bleeding disorders, progressive neurological deficits or cancer within the past five years are not treated.
- Fluoroscopic guidance for every spinal injection to confirm needle position.
- Strict sterile technique in a hospital-level environment.
- Experienced specialists: spinal procedures are performed by a pain medicine and interventional specialist rather than a general practitioner.
- Appropriate dosing: avoiding excessive volume in the confined disc space, which can increase post-procedure pain.
- Quality-controlled cells: donor screening, infectious disease testing, and laboratory quality testing before release.
- Observation and clear instructions for recovery, including warning signs.
Factors that increase risk
- Taking blood thinners or having a bleeding disorder.
- Diabetes, smoking, obesity or immune suppression, which increase infection risk.
- Previous spinal surgery, such as fusion or disc replacement, which changes anatomy and must be reviewed.
- Severe spinal stenosis or instability.
- Pregnancy, in which elective spinal procedures are not performed.
What happens on the procedure day
You arrive fasting and have your vital signs checked. The doctor reviews your MRI and confirms the levels to be treated. In the procedure room, you lie face down, the skin is cleaned with antiseptic, and sterile drapes are placed. Mild sedation and local anesthetic keep you comfortable. Using fluoroscopy, the specialist advances a thin needle to each target, confirms the position on the screen, and injects the cells, often combined with PRP. The procedure usually takes under an hour, depending on the number of levels. Afterward, you rest under observation while the sedation wears off, and the team checks your leg or arm strength and sensation before you leave the procedure area.
Recovery: protecting the treated discs
Healing after an intradiscal injection takes time. Typical guidance includes resting on the day of treatment and the following day, avoiding lifting, twisting and long drives for the first weeks, walking short distances on flat ground as tolerated, and starting guided core and mobility exercises around the second week, with gradual progression. Avoid anti-inflammatory painkillers and supplements for the period indicated, as well as alcohol for at least two weeks. Good posture, regular movement breaks and a gradual return to work help protect the treated levels. If your job involves heavy lifting or prolonged driving, discuss modified duties or extra time off with the doctor before treatment, so you can plan your recovery realistically.
Safety in context: other options for disc-related pain
Every treatment for back pain carries some risk. The UK's National Institute for Health and Care Excellence (NICE) guideline on low back pain recommends exercise, manual therapy as part of a package, psychological approaches and selected medications, while spinal surgery is reserved for specific situations. Surgery such as fusion has its own risks and recovery time. Regenerative injections sit between conservative care and surgery: less invasive than surgery, but with procedure risks that must be understood. The FDA notes that no stem cell products are approved in the United States for back pain, and in Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS.
Who may be a safe candidate
- Chronic back or neck pain linked to disc degeneration on a recent MRI.
- No severe instability, progressive weakness or bladder or bowel symptoms (which require urgent surgical evaluation).
- No active infection, uncontrolled bleeding risk or cancer within the past five years.
- Blood thinners reviewed and managed with medical oversight.
Signs to report after treatment
Seek prompt care or contact the team for fever, increasing back pain after the first week instead of gradual improvement, new weakness or numbness, loss of bladder or bowel control, severe headache when sitting or standing, or redness or discharge at needle sites.
Questions to ask during your evaluation
- Which levels and structures will be treated, and why?
- Will fluoroscopic guidance be used, and where will the procedure take place?
- Who will perform the procedure, and what is their experience?
- What are my personal risk factors, and how are they managed?
- What recovery plan should I follow?
Bottom line
Stem cell therapy for degenerative disc disease has shown a favorable safety profile in randomized trials, with temporary pain flare as the most common side effect and procedure-related complications being rare. Safety depends on careful selection, fluoroscopic guidance, sterile technique, experienced specialists and a disciplined recovery. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your spine, symptoms and medical history.
References
- Rahyussalim et al. Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials. Asian Spine Journal, 2026 (opens in a new tab)
- NICE guideline NG59: Low back pain and sciatica in over 16s, assessment and management (opens in a new tab)
- U.S. Food and Drug Administration (FDA): Consumer alert on regenerative medicine products including stem cells and exosomes (opens in a new tab)
